ATAI Stock Intrinsic Value – ATAI LIFE SCIENCES NV Reports Third Quarter FY2023 Earnings Results
November 27, 2023
🌥️Earnings Overview
ATAI LIFE SCIENCES NV ($NASDAQ:ATAI) reported its earnings results for the third quarter of FY2023 on September 30, 2023. The company earned USD 0.1 million in revenue for the quarter, in comparison to zero revenue reported in the same quarter of the previous year. Net income was reported to be USD 44.2 million, a substantial increase from the -33.9 million reported in the same period of the prior year.
Market Price
The company’s shares opened at $1.2 and closed at $1.3, representing an increase of 9.1% from its previous closing price of $1.2. The results illustrate ATAI’s ongoing commitment to creating value for shareholders and stakeholders through its innovative business strategies. This is a testament to the company’s ongoing efforts to pursue cost-saving measures and optimize its operations in order to maximize efficiency and increase profitability. This indicates that ATAI is well-positioned to capitalize on current market trends and benefit from the increasing demand for its products and services. ATAI has been actively investing in research and development, which has enabled it to create cutting-edge products and services that are in line with current customer expectations. These investments have contributed to the company’s impressive earnings growth and increased market share in a highly competitive industry.
Additionally, ATAI is focused on expanding its presence in international markets, which is expected to further strengthen its competitive advantage in the coming years. Overall, the third quarter of FY2023 results demonstrate ATAI’s commitment to providing sustainable and responsible business solutions. The company is well-positioned to benefit from increasing demand for its products and services, while continuing to provide solutions that are aligned with customer needs. With continued focus on efficiency and cost-saving measures, ATAI is on track to achieve further growth in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for ATAI. More…
| Total Revenues | Net Income | Net Margin |
| 0.33 | -66.94 | -38150.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ATAI. More…
| Operations | Investing | Financing |
| -92.66 | 27.58 | -0.82 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ATAI. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 308.22 | 39.71 | 1.6 |
Key Ratios Snapshot
Some of the financial key ratios for ATAI are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -20230.5% |
| FCF Margin | ROE | ROA |
| -27981.1% | -17.6% | -13.7% |
Analysis – ATAI Stock Intrinsic Value
At GoodWhale, we are proud to offer a comprehensive analysis of ATAI LIFE SCIENCES NV’s financials. Our proprietary Valuation Line reveals an estimated fair value of ATAI LIFE SCIENCES NV shares at around $2.1. However, currently the stock is being traded at $1.3, creating a 37.2% opportunity for investors looking to take advantage of this undervalued stock. That said, it is important for investors to do their own due diligence before investing. More…
Peers
The company’s lead product candidate, ATAI-002, is a proprietary, orally-active small molecule that is being developed for the treatment of depression. ATAI Life Sciences NV has a strategic partnership with Janssen Pharmaceuticals, Inc. for the development and commercialization of ATAI-002. The company’s competitors include Evofem Biosciences Inc, Soligenix Inc, and Aerovate Therapeutics Inc.
– Evofem Biosciences Inc ($NASDAQ:EVFM)
Soligenix is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to treat serious inflammatory conditions and other diseases of the gastrointestinal tract. The company’s lead product candidates are SGX301, an investigational new drug for the treatment of cutaneous T-cell lymphoma, and SGX942, an investigational new drug for the treatment of oral mucositis.
– Soligenix Inc ($NASDAQ:SNGX)
Aerovate Therapeutics Inc is a clinical stage biopharmaceutical company developing gene therapies for the treatment of rare, life-threatening diseases. The company’s most advanced product candidate is AERO-101, an adeno-associated virus (AAV) based gene therapy in development for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is a rare, inherited disease that can lead to liver damage and lung disease. There are currently no approved treatments for AATD.
Aerovate has a market cap of 513.41M as of 2022 and a return on equity of -15.06%. The company is developing gene therapies for the treatment of rare, life-threatening diseases.
Summary
Investors should be encouraged by the results of ATAI LIFE SCIENCES NV’s third quarter of FY2023, as total revenues increased to USD 0.1 million, compared to last year’s 0.0 million, while net income rose to USD 44.2 million, compared to -33.9 million in the same quarter of the previous year. This result is a positive reflection of the company’s growth and performance, and may indicate a strong potential for future gains. The stock price rose following the news in response to this news, suggesting that investors are bullish on the company’s outlook. Thus, those looking to add ATAI LIFE SCIENCES NV to their portfolio should do their due diligence in order to assess the company’s potential for long-term growth and profitability.
